Features | Partner Sites | Information | LinkXpress
Sign In
Schiller
GLOBETECH PUBLISHING LLC
Ampronix

Simplified Alzheimer’s Disease Diagnosis Using PET Imaging and More Effective Criteria

By Medimaging International staff writers
Posted on 24 Jul 2014
According to French investigators, over one-third of patients receive an incorrect diagnosis of Alzheimer’s disease (AD). To reduce the number of errors, the diagnostic criteria available must be the most reliable possible, especially at the very early stages of the disease. For the past 10 years, an international team of neurologists has been working towards this objective. The researchers recently introduced new diagnostic criteria, in particular, biomarkers. These are authentic signatures of the disease, and are present from the first symptoms (prodromal stage).

In the June 2014 issue of the Lancet Neurology journal, Dr. Bruno Dubois, from the National de la Santé et de la Recherche Médicale (Inserm; Paris, France) and Pierre and Marie Curie University (Paris, France) /AP-HP Joint Research Unit 975) and colleagues have developed a simplified diagnosis based on the most specific criteria of the disease, which should have a major impact in clinical practice.

AD is the most common (70%) form of dementia. The real challenge of a definitive diagnosis is to know how to differentiate this disease from other types of dementia, and establish the diagnosis as effectively and as early as possible.

In 2005, an international group of neurologists, coordinated by Inserm’s Dr. Bruno Dubois, came together to redefine the diagnostic criteria established in 1984. Up to then, it had been necessary to await the death of a patient in order to establish a diagnosis of AD with certainty by examining the lesions in his/her brain. And in the living, only a probability of disease could be inferred, and only at a late stage, based on a certain threshold of severity of dementia.

In 2007, the international team broke these hypotheses apart. The researchers introduced new diagnostic criteria, particularly biomarkers. These are authentic signatures of the disease, and are present from the initial symptoms (prodromal stage). The publication of these findings initiated a transformation. Researchers then observed that with these new criteria, “36% of their patients included in a therapeutic trial based on previous clinical criteria did not have Alzheimer’s disease,” reported Prof. Dubois. However, although this analysis involved only a subgroup of patients, the implications are serious. Patients did not receive the correct treatment and/or care. Moreover, flawed patient selection might have had an impact on the lack of efficacy observed for the new treatment.

Since 2007, many studies have been published. The international group decided to analyze this literature to make the diagnostic algorithm for AD simpler and more reliable. “We have reached the end of the road; we have arrived at the essence, something refined, resulting from an international consensus,” indicated Prof. Dubois. The diagnosis of Alzheimer’s disease will henceforth rely on “just a couple of clinical-biological criteria for all stages of the disease.”

Most of the time, the diagnosis of AD is based primarily on a suggestive clinical picture. It is subsequently confirmed or rejected using a biomarker. As regards the clinical picture, there are three scenarios: (1) typical cases (80%–85% of all cases): impairment of episodic long-term memory (known as amnestic syndrome of the hippocampal type and corresponding to difficulty remembering a list a words, even with clues, for example); (2) atypical cases (15%–20% of cases): atrophy of the posterior part of the cerebral cortex or logopenic aphasia (impairment of verbal memory where the patient inverts the syllables of a word when repeating it, for example), or frontal brain damage, which results in behavioral problems; (3) preclinical states: asymptomatic at-risk (patients without symptoms, but who are fortuitously discovered to have positive biomarkers during scientific studies), and presymptomatic (with a genetic mutation).

One of the following two biomarkers is required: (1) in the cerebrospinal fluid (obtained by lumbar puncture) to ascertain abnormal levels of brain proteins (reduced beta amyloid protein and increased tau protein); (2) and in the brain by positron emission tomography (PET) neuroimaging to determine the elevated retention of amyloid tracer.

This simpler and more effective algorithm is important, mainly for research (therapeutic trials, characterization of the disease, monitoring of patient cohorts), according to the investigators. Outside of research, the use of biomarkers, which is expensive and/or invasive, currently remains limited to young patients or difficult or complex cases in specialty centers.

Related Links:
National de la Santé et de la Recherche Médicale
Pierre and Marie Curie University




Channels

Radiography

view channel
Image: Bayalpata Hospital in Rural Nepal (Photo courtesy of Nyaya Health Blog).

Base of the Pyramid Digital Imaging System Built for Novel Telemedicine Applications

The remote Bayalpata Hospital in the mountains of Western Nepal has set up a system that will allow their physicians to digitize and send X-ray images to physicians in Grande hospital in Kathmandu for... Read more

MRI

view channel
Image: Using an MRI technique that is sensitive to certain byproducts of cell metabolism, including levels of glucose and acidity, University of Iowa researchers discovered previously unrecognized differences in the brains of patients with bipolar disorder. The T1rho MRI scans showed brain regions of elevated signal in the 15 participants with bipolar disorder compared to the 25 participants who did not have bipolar disorder. The primary regions of difference are the cerebral white matter (yellow) and the cerebellum (red) (Photo courtesy of the University of Iowa).

Quantitative, High-Resolution T1 Rho MRI Mapping Scan Reveals Brain Differences in Bipolar Disorder

Using a different sort of magnetic resonance imaging (MRI) technology, researchers have discovered previously unrecognized differences in the brains of patients with bipolar disorder. In particular, the... Read more

Ultrasound

view channel

Guidelines Released for Quantitative Monitoring of Critically Ill and Surgery Patients Using Echocardiography

The American Society of Echocardiography (ASE; Morrisville, NC, USA) has published clinical guidelines describing how and when echocardiography can be used for medical and surgical therapy in adult patients. The guidelines were published in the January 2015 issue of the American Society of Echocardiography.... Read more

General/Advanced Imaging

view channel
Image: Dr. Miles was part of the team that helped identify facial measurements in children with autism that may lead to a screening tool for young children and provide clues to its genetic causes (Photo courtesy of Rebecca F. Miller).

Advanced 3D Facial Imaging Designed to Help in Early Identification of Autism

Autism is a range of closely related disorders observed in patients who exhibit a shared assortment of symptoms, including delays in learning to communicate and interrelate socially. Early detection of... Read more

Imaging IT

view channel

Findings Reveal Health Information Exchange Decreases Repeat Imaging

The use of health information exchange (HIE) systems to share reports on imaging tests, such as X-rays and magnetic resonance imaging (MRI) scans, can help reduce the number of times patients undergo the precisely same test. A new study suggests that HIE technology that gives healthcare providers immediate, electronic access... Read more

Industry News

view channel
Image: 3-D Image of the Mindray DC-70 Ultrsound System (Photo courtesy of Mindray).

Ultrasound Equipment Sector in United States Expected to Grow Through 2020

Ultrasound equipment market in the United States is expected to remain stable and continue to grow, exceeding USD 2 billion by 2020 as revealed in a report by iData Research (Burnaby, BC, Canada).... Read more
 

Events

01 Feb 2015 - 06 Feb 2015
02 Feb 2015 - 06 Feb 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.